myeloproliferative neoplasm (Cancer)
Information
- Disease name
- myeloproliferative neoplasm
- Disease ID
- DOID:2226
- Description
- "A myeloid neoplasm that is characterized by a group of slow growing blood cancers in which large numbers of abnormal red blood cells, white blood cells, or platelets grow and spread in the bone marrow and the peripheral blood." [url:http\://www.bloodjournal.org/content/114/5/937.long, url:http\://www.cancer.gov/cancertopics/types/myeloproliferative]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03192397 | Active, not recruiting | Phase 1/Phase 2 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | August 9, 2017 | May 21, 2027 |
| NCT03238248 | Active, not recruiting | Phase 2 | Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors | August 7, 2017 | October 3, 2024 |
| NCT03333486 | Active, not recruiting | Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | December 7, 2017 | August 28, 2024 |
| NCT04191187 | Active, not recruiting | Phase 2 | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies | December 6, 2019 | February 2025 |
| NCT03386513 | Active, not recruiting | Phase 1/Phase 2 | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | January 2, 2018 | December 2025 |
| NCT05972577 | Active, not recruiting | N/A | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | June 2, 2021 | December 31, 2024 |
| NCT02566304 | Active, not recruiting | Phase 2 | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | November 13, 2015 | February 13, 2024 |
| NCT03862157 | Active, not recruiting | Phase 1/Phase 2 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | February 27, 2019 | January 31, 2025 |
| NCT04060277 | Active, not recruiting | Phase 2 | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | November 27, 2019 | April 7, 2030 |
| NCT04041050 | Active, not recruiting | Phase 1 | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | November 8, 2019 | January 29, 2025 |
| NCT02506933 | Active, not recruiting | Phase 2 | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant | November 5, 2015 | December 30, 2024 |
| NCT02521493 | Active, not recruiting | Phase 3 | Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | December 23, 2015 | June 30, 2024 |
| NCT02396134 | Active, not recruiting | Phase 2 | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | May 21, 2015 | December 31, 2024 |
| NCT02728050 | Completed | Phase 1/Phase 2 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | December 1, 2016 | April 4, 2023 |
| NCT02862366 | Completed | Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1- | October 2010 | January 25, 2016 | |
| NCT02960646 | Completed | Phase 1 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | January 18, 2017 | February 13, 2023 |
| NCT03072043 | Completed | Phase 1/Phase 2 | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | May 18, 2017 | December 8, 2021 |
| NCT03128359 | Completed | Phase 2 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | May 30, 2017 | September 15, 2021 |
| NCT05825326 | Completed | Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador | January 1, 2012 | December 31, 2019 | |
| NCT03397173 | Completed | Phase 2 | TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid | March 16, 2018 | January 21, 2021 |
| NCT04942730 | Completed | Phase 2 | Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) | January 21, 2021 | April 30, 2024 |
| NCT04744974 | Completed | Phase 2 | Remotely Administered Diet Intervention to Impact Symptom Burden in Myeloproliferative Neoplasm | January 21, 2021 | December 6, 2021 |
| NCT04666025 | Completed | SARS-CoV-2 Donor-Recipient Immunity Transfer | September 23, 2020 | May 5, 2023 | |
| NCT04629430 | Completed | N/A | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT | February 19, 2021 | October 28, 2022 |
| NCT04605211 | Completed | N/A | A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors | September 18, 2020 | September 30, 2022 |
| NCT04416438 | Completed | COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias | May 18, 2020 | September 1, 2022 | |
| NCT04192916 | Completed | Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms | September 1, 2019 | December 31, 2020 | |
| NCT03726944 | Completed | N/A | The Feasibility of Delivering Consumer-based Meditation Applications to Myeloproliferative Neoplasm Patients | July 31, 2017 | April 2, 2018 |
| NCT04177576 | Completed | Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms | February 24, 2020 | January 26, 2022 | |
| NCT04146038 | Completed | Phase 2 | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | October 26, 2020 | October 25, 2022 |
| NCT03941769 | Completed | Phase 1/Phase 2 | 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II | September 29, 2020 | March 1, 2023 |
| NCT04014764 | Completed | Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy | December 15, 2019 | March 31, 2022 | |
| NCT00397813 | Completed | Phase 2 | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders | January 2006 | March 2018 |
| NCT04022785 | Completed | Phase 1 | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | September 9, 2019 | October 24, 2022 |
| NCT00723099 | Completed | Phase 2 | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | June 25, 2008 | July 31, 2018 |
| NCT01231412 | Completed | Phase 3 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | November 2010 | June 30, 2017 |
| NCT01362985 | Completed | Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor | July 2009 | July 2014 | |
| NCT01822509 | Completed | Phase 1 | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | May 16, 2013 | June 10, 2021 |
| NCT01951885 | Completed | Phase 3 | Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention | July 7, 2014 | August 11, 2021 |
| NCT02029950 | Completed | Phase 1 | Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | December 16, 2013 | May 13, 2020 |
| NCT02121418 | Completed | N/A | Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm | June 2014 | February 14, 2018 |
| NCT02311569 | Completed | Phase 2 | Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | April 2015 | December 2016 |
| NCT06371573 | Completed | Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms | April 20, 2017 | March 20, 2024 | |
| NCT02424968 | Completed | Phase 2 | CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma | June 2015 | April 2021 |
| NCT06159816 | Completed | PREVALENCE STUDY OF PNH CLONES IN PATIENTS WITH NEOPLASIES | November 1, 2017 | January 1, 2022 | |
| NCT02639559 | Completed | Phase 2 | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | March 31, 2016 | April 7, 2023 |
| NCT04024761 | Enrolling by invitation | Phase 1 | A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation | August 31, 2019 | December 1, 2024 |
| NCT04994158 | Enrolling by invitation | MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis | September 1, 2019 | September 1, 2034 | |
| NCT04378855 | Not yet recruiting | Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY). | May 2020 | May 2025 | |
| NCT06284460 | Not yet recruiting | Phase 1/Phase 2 | Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms | July 31, 2024 | December 1, 2027 |
| NCT06177366 | Not yet recruiting | A New Blood Score for Myelofibrosis Staging | February 1, 2024 | February 1, 2026 | |
| NCT04451200 | Not yet recruiting | Phase 2 | Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning | November 2020 | December 2028 |
| NCT06421155 | Not yet recruiting | N/A | Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia | July 31, 2024 | November 14, 2028 |
| NCT06334913 | Not yet recruiting | A Prospective Patient Reported Outcomes and Wearables Study in Myeloproliferative Neoplasms | April 1, 2024 | April 1, 2029 | |
| NCT06022341 | Not yet recruiting | N/A | MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies | October 15, 2023 | December 31, 2028 |
| NCT05745285 | Not yet recruiting | N/A | Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | July 1, 2024 | November 1, 2025 |
| NCT03939585 | Not yet recruiting | Phase 1 | Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT | June 1, 2024 | June 1, 2026 |
| NCT05440838 | Not yet recruiting | Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis. | September 8, 2022 | October 4, 2029 | |
| NCT06290765 | Not yet recruiting | Phase 4 | Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Low-Risk Polycythemia Vera | July 1, 2024 | February 28, 2027 |
| NCT06138587 | Recruiting | Phase 1 | Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation | January 24, 2024 | November 30, 2026 |
| NCT04060485 | Recruiting | Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results | August 19, 2019 | December 31, 2024 | |
| NCT04103645 | Recruiting | Phase 2 | Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients | November 22, 2019 | September 1, 2025 |
| NCT03630991 | Recruiting | Phase 1 | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy | October 11, 2018 | April 30, 2025 |
| NCT03622788 | Recruiting | Phase 1/Phase 2 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | August 8, 2019 | December 1, 2025 |
| NCT04279847 | Recruiting | Phase 1 | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms | February 23, 2021 | December 31, 2024 |
| NCT04282187 | Recruiting | Phase 2 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | March 24, 2020 | November 11, 2026 |
| NCT04493138 | Recruiting | Phase 1/Phase 2 | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | July 21, 2020 | December 31, 2025 |
| NCT04493164 | Recruiting | Phase 2 | CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | December 30, 2020 | June 1, 2025 |
| NCT03589729 | Recruiting | Phase 2 | Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | September 19, 2018 | December 31, 2025 |
| NCT05521204 | Recruiting | Phase 2 | Olverembatinib for FGFR1-rearranged Neoplasms | September 1, 2022 | August 31, 2027 |
| NCT05600894 | Recruiting | Phase 2 | Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm | June 27, 2023 | August 31, 2025 |
| NCT05714592 | Recruiting | N/A | Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities | January 27, 2023 | January 2025 |
| NCT05732961 | Recruiting | Phase 2 | Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms | February 21, 2023 | May 2025 |
| NCT05805605 | Recruiting | Phase 2 | Allo HSCT Using RIC and PTCy for Hematological Diseases | May 1, 2023 | October 22, 2028 |
| NCT05839717 | Recruiting | Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK) | June 19, 2023 | December 2024 | |
| NCT05850273 | Recruiting | Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms | March 16, 2023 | March 16, 2033 | |
| NCT05882773 | Recruiting | Asian Myeloproliferative Neoplasm (MPN) Registry | May 2023 | December 2026 | |
| NCT05993052 | Recruiting | Carotid Plaque Burden in Patients With Philadelphia Negative Myeloproliferative Neoplasms | December 15, 2022 | September 2023 | |
| NCT06001385 | Recruiting | Phase 2 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | December 8, 2023 | June 30, 2026 |
| NCT06013423 | Recruiting | Phase 2 | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | July 6, 2024 | October 31, 2025 |
| NCT06022328 | Recruiting | Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC) | December 15, 2023 | December 2024 | |
| NCT06034470 | Recruiting | Phase 1 | Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms | December 18, 2023 | December 31, 2027 |
| NCT06059391 | Recruiting | Phase 2 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | August 30, 2024 | January 1, 2028 |
| NCT06131801 | Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | November 15, 2023 | December 1, 2027 | |
| NCT03878199 | Recruiting | Phase 1/Phase 2 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | February 20, 2019 | December 31, 2024 |
| NCT06361641 | Recruiting | N/A | Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes | May 29, 2024 | October 19, 2027 |
| NCT02402244 | Recruiting | Project: Every Child for Younger Patients With Cancer | November 3, 2015 | December 31, 2030 | |
| NCT03471260 | Recruiting | Phase 1/Phase 2 | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | March 19, 2018 | September 30, 2025 |
| NCT03452774 | Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | January 1, 2018 | June 2027 | |
| NCT04802161 | Recruiting | Phase 2 | Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes | August 24, 2022 | December 31, 2024 |
| NCT04898790 | Recruiting | N/A | Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant | November 18, 2021 | April 2025 |
| NCT04902833 | Recruiting | Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms | February 1, 2022 | December 31, 2025 | |
| NCT04942080 | Recruiting | N/A | Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) | October 28, 2021 | April 28, 2026 |
| NCT04943757 | Recruiting | Phase 2 | Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies | January 21, 2021 | December 31, 2024 |
| NCT04955938 | Recruiting | Phase 1 | A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | October 29, 2021 | October 1, 2025 |
| NCT06462664 | Recruiting | Exploring the Impact of Monocytes in Myeloproliferative Neoplasia (EMYNEM) | June 1, 2024 | January 31, 2028 | |
| NCT05053100 | Recruiting | Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study | August 17, 2021 | August 18, 2025 | |
| NCT05074355 | Recruiting | Phase 2 | Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms | November 8, 2023 | December 31, 2025 |
| NCT05120570 | Recruiting | Phase 1/Phase 2 | PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation | March 17, 2022 | March 31, 2028 |
| NCT05123365 | Recruiting | Phase 1/Phase 2 | An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms | January 3, 2022 | November 15, 2026 |
| NCT05127174 | Recruiting | Phase 1/Phase 2 | Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms | March 14, 2022 | November 2025 |
| NCT05177211 | Recruiting | Phase 2 | Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) | March 1, 2022 | December 2025 |
| NCT05364762 | Recruiting | Phase 2 | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | November 23, 2022 | April 28, 2024 |
| NCT05419648 | Recruiting | Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr) | October 5, 2022 | October 2024 | |
| NCT05455294 | Recruiting | Phase 1 | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | July 18, 2022 | December 31, 2026 |
| NCT05107856 | Terminated | Phase 1 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | March 22, 2022 | January 19, 2024 |
| NCT04637009 | Terminated | Phase 1 | A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms | December 21, 2020 | February 20, 2023 |
| NCT05524857 | Terminated | Phase 1 | Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP) | January 28, 2022 | April 9, 2024 |
| NCT02877082 | Terminated | Phase 2 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | September 2016 | July 2017 |
| NCT03795779 | Unknown status | Early Phase 1 | CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | March 1, 2018 | September 30, 2022 |
| NCT04156256 | Unknown status | Early Phase 1 | CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | March 1, 2018 | September 30, 2020 |
| NCT03588078 | Unknown status | Phase 1/Phase 2 | Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine | September 15, 2018 | May 15, 2021 |
| NCT04631458 | Unknown status | Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis | November 12, 2014 | December 30, 2021 | |
| NCT04312607 | Unknown status | Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm | August 1, 2020 | March 1, 2022 | |
| NCT03177928 | Unknown status | N/A | Cardiac Changes in Myeloproliferative Neoplasms | September 1, 2017 | February 28, 2019 |
| NCT04385160 | Unknown status | Myeloproliferative Neoplasms (MPN) and COVID-19 | May 13, 2020 | August 31, 2022 | |
| NCT04527666 | Unknown status | Anticoagulation in Gastroesophageal Varices and JAK2 Mutation | October 1, 2020 | September 30, 2022 | |
| NCT04525768 | Unknown status | Gastroesophageal Varices in Cavernoma | October 1, 2020 | September 30, 2022 | |
| NCT03438344 | Withdrawn | Phase 2 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | December 2018 | December 2021 |
| NCT04629651 | Withdrawn | Phase 1/Phase 2 | Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms | April 2024 | October 2024 |
| NCT03807063 | Withdrawn | Phase 1 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | January 2, 2020 | December 31, 2021 |
| NCT02564536 | Withdrawn | Phase 1 | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | June 2017 | June 30, 2020 |
| NCT03602898 | Withdrawn | Phase 2 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | June 1, 2021 | September 17, 2023 |
- Disase is a (Disease Ontology)
- DOID:0070004
- Cross Reference ID (Disease Ontology)
- ICD10CM:D47.1
- Cross Reference ID (Disease Ontology)
- ICDO:9960/3
- Cross Reference ID (Disease Ontology)
- NCI:C4345
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:115248004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1292778
- Exact Synonym (Disease Ontology)
- chronic myeloproliferative disease
- Exact Synonym (Disease Ontology)
- CMPD
- Exact Synonym (Disease Ontology)
- CMPD, U